18th week of 2020 patent applcation highlights part 8 |
Patent application number | Title | Published |
20200129422 | Progesterone in Bioadhesive Formulation for Buccal Delivery - A pharmaceutical mucoadhesive gel composition for delivering therapeutic agents (such as progesterone) by buccal, nasal, vaginal and rectal administration, thereby avoiding the hepatic first-pass metabolism. The gel composition comprises a vehicle with a gel-forming agent and a bioadhesive agent; and a therapeutic agent dispersed or suspended in the vehicle. | 2020-04-30 |
20200129423 | DONEPEZIL PAMOATE, PREPARATION METHODE AND ITS USE - The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed. | 2020-04-30 |
20200129424 | MICRONEEDLE SYSTEM FOR APPLYING GLUCAGON-LIKE PEPTIDE ANALOGUES - The present invention relates to a microneedle system (MNS) for intradermal application in a controlled release of glucagon-like peptide analogues. | 2020-04-30 |
20200129425 | SHORT DURATION DEPOT FORMULATIONS - Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent. | 2020-04-30 |
20200129426 | PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION - The purpose of the present invention is to provide a dosing technique for rifampicin, the technique being capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and by suppressing the hepatic first-pass effect. This pharmaceutical composition for nasal administration, which contains, as an active ingredient, rifampicins selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and is used for the prevention or treatment of dementia, is capable of long-term administration by enhancing the direct transfer of rifampicin to the brain and suppressing the hepatic first-pass effect. | 2020-04-30 |
20200129427 | METHOD FOR MANUFACTURING MEDICATED CHEWING GUM WITHOUT COOLING - An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapcutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described. | 2020-04-30 |
20200129428 | ANTIFUNGAL DRY POWDERS - The invention relates to dry powder formulations comprising respirable dry particles that contain 1) an antifungal agent in crystalline particulate form, 2) a stabilizer, and 3) one or more excipients. | 2020-04-30 |
20200129429 | BIOCOMPATIBLE AND BIODEGRADABLE EMULSIONS AND COMPOSITIONS, AND METHODS OF USE THEREOF - Emulsions and layered compositions for improving thermal resistance of a substrate, such as a therapeutic or prophylactic medicinal substrate, are provided. Also provided are methods and kits for making the emulsions and layered compositions of the invention. The layered compositions and emulsions can be used to extend the shelf life of a product. | 2020-04-30 |
20200129430 | Methods and Compositions for Administering an Active Agent to the Pleura of a Patient - A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura. | 2020-04-30 |
20200129431 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO siRNA CELL - A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): | 2020-04-30 |
20200129432 | POLYNUCLEOTIDE ENCAPSULATION AND PRESERVATION USING SELF-ASSEMBLING MEMBRANES - Polynucleotides such as DNA are stored inside vesicles formed from self-assembling membranes. The vesicles may be protocells, liposome, micelles, colloidosomes, proteinosomes, or coacervates. The vesicles may include surface functionalization to improve polynucleotide encapsulation and/or to bind polynucleotides having specific sequences. Encapsulation in vesicles provides protection for the polynucleotides. Additional protection is provided by addition of one or more stabilizers. The stabilizer may be nucleic-acid stabilizers that stabilize the polynucleotides or may be a protective structural layer around the vesicles such as a layer of silica. A process for stably storing polynucleotides in vesicles and a process for recovering stored polynucleotides from vesicles are both disclosed. The polynucleotides may be used for storage of digital information. | 2020-04-30 |
20200129433 | STEM CELL-DERIVED MICROVESICLES WITH ENHANCED EFFICACY, USE THEREOF, AND METHOD FOR ENHANCING EFFICACY - The present invention relates to stem cell-derived microvesicles with enhanced efficacy, a use thereof, and a method for enhancing efficacy, and more particularly, to a use of stem cell-derived microvesicles with an enhanced expression level of microRNAs for the prevention or treatment of stroke, and a method for promoting the production of microRNAs of stem cell-derived microvesicles and enhancing efficacy, and a method for promoting the production of stem cell-derived microvesicles and microRNAs within the microvesicles and enhancing the efficacy of stem cells and microvesicles thereof by 3-dimensionally culturing or ischemically stimulating stem cells. Since the method according to the present invention has excellent effects capable of promoting the production of stem cell-derived microvesicles and microRNAs in the microvesicles and capable of enhancing the efficacy of stem cells or microvesicles isolated therefrom, it is possible to obtain stem cell-derived microvesicles containing high levels of materials including therapeutic microRNAs efficiently and in large quantities through this, and thus, the microvesicles are expected to be able to be usefully used in related research fields and future clinical settings. | 2020-04-30 |
20200129434 | LIPOSOME COMPOSITIONS AND USES THEREOF - The present invention provides compositions comprising liposomes comprises cholesterol, phosphatidyl phosphoric acid and phosphatidyl choline, as well as liposomes comprising a drug or imaging agent and a peptide for targeting to the brain. The invention further provides methods for treating or ameliorating a brain disease by administering the compositions of the invention. | 2020-04-30 |
20200129435 | COMPOSITION FOR DELIVERING A THERAPEUTIC AGENT AND METHODS FOR MAKING AND USING - Disclosed herein are embodiments of a composition comprising a matrix, a plurality of microparticles and a therapeutic agent. The therapeutic agent may be encapsulated in the microparticles, and/or the microparticles may be dispersed in the matrix. The composition may be a mesh or a sheet, and may further comprise a second therapeutic agent, and optionally a second microparticle and/or a second matrix. In particular embodiments, the matrix is a hydrogel. Methods for making and using the composition are also disclosed, and in certain embodiments, the composition is useful for treating cancer, such as brain cancer. | 2020-04-30 |
20200129436 | Viral Vector Stabilization - Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature. | 2020-04-30 |
20200129437 | DRY-BINDERS FOR TABLETS BASED ON POLYETHYLENE GLYCOL-POLYVINYL ALCOHOL GRAFT POLYMERS, THE PRODUCTION AND USE THEREOF - A finely divided binder in powder form consisting of a polyethylene glycol-polyvinyl alcohol graft polymer particles, wherein the particles have an average particle size D[4,3] in the range of from 10 to 70 μm. | 2020-04-30 |
20200129438 | FINISHED PHARMACEUTICAL DOSAGE FORM COMPRISING A LOW DOSE/HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENT AND ONE OR MORE EXCIPIENTS - The present application discloses a finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients. The active pharmaceutical ingredient in the present application has been blended and subsequently milled with at least one excipient before preparing the finished pharmaceutical dosage form. The disclosed finished dosage form promotes content uniformity and acceptable and reproducible dissolution rate and extent. Finished dosage forms of the present invention may comprise any active pharmaceutical ingredient; however, low solubility and/or high potency active pharmaceutical ingredients will particularly benefit. Among the low solubility and/or high potency active pharmaceutical ingredients, those with needle-like structures are even more particularly well suited for incorporation into the disclosed finished dosage forms. A finished dosage form containing ivermectin is one non-limiting example of a finished dosage form contemplated by the disclosure herein. Hormonal steroids are also particularly well suited for the invention described herein. | 2020-04-30 |
20200129439 | Controlled Release Dosage Form with Enhanced Pharmacokinetics - The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA | 2020-04-30 |
20200129440 | COMPLEX FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND CLOPIDOGREL - The present invention relates to a complex preparation comprising clopidogrel, an HMG-CoA reductase inhibitor, and a separation membrane containing a hydrophobic compound. More particularly, an objective of the present invention is to provide the complex preparation comprising clopidogrel and the HMG-CoA reductase inhibitor, wherein the complex preparation is intended for preventing or treating a cardiovascular disease, which has excellent storage stability by preventing a decrease in the stability of the HMG-CoA reductase inhibitor. | 2020-04-30 |
20200129441 | SELF-RIGHTING SYSTEMS AND RELATED COMPONENTS AND METHODS - Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface. The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage with a surface. In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. | 2020-04-30 |
20200129442 | POLYMER BASED FORMULATION FOR RELEASE OF DRUGS AND BIOACTIVES AT SPECIFIC GIT SITES - The present invention is related to polymer based formulation for release of drugs and bioactives at gastrointestinal tract specific sites including stomach, intestine and colon. | 2020-04-30 |
20200129443 | COILED TUBE EMULSIFICATION METHODS - Embodiments of the present technology may include a method of forming an emulsion. The method may include flowing an oil stream and an aqueous stream into a coiled tube to form a mixture of an oil phase and an aqueous phase in the coiled tube. The method may also include flowing the mixture in the coiled tube against gravity and under laminar conditions. A plurality of beads may be disposed within the coiled tube. The method may further include mixing the oil phase and the aqueous phase in the coiled tube until the emulsion is formed. | 2020-04-30 |
20200129444 | Method of Increasing Epithelial Permeability Using Nanoparticles - Provided herein are devices and dosage forms useful in delivering macromolecular active ingredients or drugs, such as proteins, peptides and nucleic acids, through epithelial membranes, such as intestinal epithelium. Also provided are trans-epithelial drug delivery methods and methods of treatment of diabetes or insulin resistance, or to induce weight loss. | 2020-04-30 |
20200129445 | LIPID NANOPARTICLE FORMULATION - The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. | 2020-04-30 |
20200129446 | RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYANHYDRIDE NANOPARTICLE VACCINE - Disclosed are compositions and methods for vaccinating susceptible individuals against infection by respiratory syncytial virus (RSV). The disclosed compositions include vaccine compositions comprising an effective amount of respiratory syncytial virus (RSV) F protein in a pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles for inducing an immune response against RSV. The vaccine compositions also may include a suitable adjuvant. | 2020-04-30 |
20200129447 | TAGGED POLY(ESTER AMIDE URETHANE)S, NANOPARTICLES FORMED FROM SAME, AND USES THEREOF - Provided are polymers (e.g., polymeric materials), nanoparticles comprising one or more of the polymers, and compositions. A polymer may be in the form of a nanoparticle. A polymer can be linear or branched. A polymer includes one or more poly(ester urea) segment, optionally, one or more poly(urethane) segment, optionally, one or more diol segment, optionally, one or more poly(ethylene glycol) segment, and, optionally, one or more terminal/end group. A polymer (e.g., a polymeric material) may include a branching moiety. For example, a composition includes one or more polymer. In an example, polymers and nanoparticles can be used to deliver a drug (e.g., gambogic acid) to an individual (e.g, who has been diagnosed with or is suspected of having cancer and/or a viral infection). | 2020-04-30 |
20200129448 | COMPOSITIONS AND METHODS FOR WOUND CLOSURE - The current disclosure provides compositions and methods for wound closure. The disclosure provides an device comprising: a) a material with a surface comprising a modified fibrinogen or a modified fibrin, wherein the modified fibrinogen or modified fibrin is more resistant to fibrinolysis than an unmodified fibrinogen or an unmodified fibrin, respectively; and b) one or more dispersible fibrinolysis inhibitors in contact with the surface comprising a plasmin inhibitor; and c) optionally, a thrombin agent or platelets. | 2020-04-30 |
20200129449 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR NICOTINE CESSATION AND CHEMOPREVENTION - Compounds, compositions, and methods of use of such compounds and compositions are provided for reducing human dependency to nicotine. In one example, a method of treating an individual with an addiction to nicotine comprises administering to the individual a compound that is a structural analog of trans-cinnamaldehyde. Based on the administration, a rate at which nicotine is metabolized may be reduced, which in turn may reduce a desire for the individual to consume nicotine-containing products. | 2020-04-30 |
20200129450 | COMPOSITION COMPRISING OSMUNDACETONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR PREVENTING OR TREATING BONE DISEASE - The present invention relates to a composition comprising osmundacetone or a pharmaceutically acceptable salt thereof for preventing or treating bone diseases. More specifically, the present invention relates to: a composition comprising osmundacetone, a pharmaceutically acceptable salt thereof, or an | 2020-04-30 |
20200129451 | MULTIRESISTANT-TUMOUR SENSITISER - The present invention refers to the use of the compound Cur-[G-2]-OH as a sensitizing agent in a wide range of multidrug-resistant tumors, especially glioblastoma, which are characterized by overexpression of the Nrf2 pathway. | 2020-04-30 |
20200129452 | SOLUBILIZATE WITH CURCUMIN AND OPTIONALLY AT LEAST ONE OTHER ACTIVE SUBSTANCE - In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases. | 2020-04-30 |
20200129453 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS - A method of treating an ocular disorder in a subject associated with increased all-trans-retinal in an ocular tissue includes administering to the subject a therapeutically effective amount of a primary amine compound of formula (I): | 2020-04-30 |
20200129454 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof. | 2020-04-30 |
20200129455 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof. | 2020-04-30 |
20200129456 | THERAPY FOR KINASE-DEPENDENT MALIGNANCIES - A pharmaceutically acceptable composition and method of therapy for a kinase-dependent malignancy in a patient in need of such therapy is provided. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, (b) an inhibitor of Dusp-1, and (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for kinase-dependent malignancy. Also provided is a method to eradicate leukemia initiating cells (LIC) or cancer stem cells (CSC) in a patient being treated with a tyrosine kinase inhibitor. | 2020-04-30 |
20200129457 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF - The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction. | 2020-04-30 |
20200129458 | COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS - Compounds represented by formula (I): | 2020-04-30 |
20200129459 | THE NEW USE OF 2-[(3Z)-6-FLUORO-2-METHYL-3-[(4-METHYLSULFINYLPHENYL) METHYLIDENE]INDEN-1 -YL] ACETIC ACID - A new use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl] acetic acid (sulindac) of the formula 1 for making the pharmaceutical preparations for the treatment of difficult healing different types of wounds in patients with diabetes. | 2020-04-30 |
20200129460 | Treatment of intrahepatic cholestatic diseases - Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof. | 2020-04-30 |
20200129461 | Compositions Comprising Cancer Drug-Fatty Acid Conjugates - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2020-04-30 |
20200129462 | COMPOSITIONS AND METHODS FOR TREATING ACNE VULGARIS - Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid, Brij®-30 and a molecular penetration enhancer in a pharmaceutically acceptable preparation. The molecular penetration enhancer may include one or more of DMSO, dimethyl isosorbide, lauryl lactate and isopropyl myristate. | 2020-04-30 |
20200129463 | ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, CANNABIDIOL, AND RELATED COMPOUNDS IN HUMANS - In various implementations, cannabidiol, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to improve the health of the individual. Other compounds may include amino acids, short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof. | 2020-04-30 |
20200129464 | Method and Composition for Increasing the Bioavailability of Carnitine - A method and composition for improving the health of a mammal, such as by increasing the bioavailability of L-carnitine to the mammal. The method and composition includes administering an effective amount of branched chain amino acid metabolite substituted carnitine compound. The method and composition also includes administering an effective amount of branched chain amino acid metabolite substituted carnitine compound in order to improve the health of the mammal. The mammal's health may be improved by providing increased energy, anti-aging, anti-inflammatory and/or anti-oxidant properties, increased mitochondrial function, increased brain function, weight management and/or obesity management properties, exercise endurance and exercise recovery, increased protein synthesis, mTOR pathway activation, and/or Kreps cycle stimulation. | 2020-04-30 |
20200129465 | AMINO ACID FORMULATIONS FOR PANCREATIC VIABILITY - Amino acid formulations for pancreatic vitality. The formulations comprise a mixture of a plurality of amino acids, wherein the mixture comprises at least one amino acid selected from the group consisting of serine, glutamic acid, and/or carnitine. Methods of enhancing pancreatic vitality, stabilizing blood glucose levels, and improving A1C levels in subjects in need thereof are also described. | 2020-04-30 |
20200129466 | Compositions and Methods for Treating Anhidrosis - Provided herein are compositions and methods useful for the treatment of anhidrosis in mammals, for example, horses. | 2020-04-30 |
20200129467 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES - Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD). | 2020-04-30 |
20200129468 | OPHTHALMIC COMPOSITION FOR GLAUCOMA TREATMENT - An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol. | 2020-04-30 |
20200129469 | METHODS OF TREATING BILIARY TRACT CANCER - The present invention provides methods and compositions for treating biliary tract cancers by administering an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin. The present invention also provides combination treatment methods of treating biliary tract cancers comprising administering an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin and an effective amount of another therapeutic agent. Also provided herein are medicines and kits thereof. | 2020-04-30 |
20200129470 | COMBINATIONS OF ARTEMISININS, BCL-2 INHIBITORS, AND KINASE INHIBITORS FOR CANCER TREATMENT - Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and one or more additional therapeutic agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, ART-631, and ART-838. The one or more additional therapeutic agents include BCL-2 inhibitors such as ABT-199, ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib, midostaurin, and sorafenib; and anti-neoplastic agents such as cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide, vinorelbine, cisplatin, and rituximab. | 2020-04-30 |
20200129471 | USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF - The present invention discloses a composition comprising cannabis natural extract, or synthetic cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the aforementioned composition. | 2020-04-30 |
20200129472 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE - Compositions and methods for the treatment of peripheral artery disease and the symptoms thereof are provided. | 2020-04-30 |
20200129473 | USE OF ERIBULIN AND CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER - The invention features methods for treating and preventing cancer (e.g., an estrogen receptor-positive (ER | 2020-04-30 |
20200129474 | COMBINATION THERAPY FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY - The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. | 2020-04-30 |
20200129475 | USE AND PHARMACEUTICAL COMPOSITION FOR LIVER FIBROSIS PREVENTION AND/OR TREATMENT - The present disclosure discloses an extract of | 2020-04-30 |
20200129476 | PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing - The present invention relates to a PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing. | 2020-04-30 |
20200129477 | METHODS OF TREATING SCHIZOPHRENIA - Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds. | 2020-04-30 |
20200129478 | TESOFENSINE AND BETA BLOCKER COMBINATION FORMULATIONS - The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder. | 2020-04-30 |
20200129479 | IDALOPIRDINE-BASED COMBINATORIAL THERAPIES OF ALZHEIMER'S DISEASE - The present invention relates to combinatorial therapies and methods for the treatment of Alzheimer's disease or an Alzheimer's disease related disorder based on idalopirdine, baclofen and acamprosate, wherein idalopirdine is provided as suboptimal doses. | 2020-04-30 |
20200129480 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS - The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. | 2020-04-30 |
20200129481 | USE AND COMPOSITION FOR TREATING MYASTHENIA GRAVIS AND OTHER MYASTHENIC SYNDROMES - The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects. | 2020-04-30 |
20200129482 | TREATMENT OF NON-SMALL CELL LUNG CANCER - The present invention provides methods of treating non-small cell lung cancer in a patient comprising administering to the patient an effective amount of a PARP inhibitor, wherein the patient is Lung Subtyping Panel (LSP) positive. | 2020-04-30 |
20200129483 | PHARMACEUTICAL COMPOSITION - Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided to contain the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-6): (B-1) a cellulose ether species; (B-2) a starch species; (B-3) a povidone species; (B-4) a silicic acid compound; (B-5) a polyhydric alcohol; and (B-6) an alkyl sulfate ester. | 2020-04-30 |
20200129484 | RAD51 INHIBITORS - This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects. | 2020-04-30 |
20200129485 | TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND - Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1. | 2020-04-30 |
20200129486 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OLMSTED SYNDROME - Olmsted syndrome (OS) is a rare genodermatosis. The disease is debilitating and progressive keratoderma and auto-amputation of digits can prevent patients from grasping and walking, and confine them to a wheelchair. New therapeutic options are therefore crucial and are expected from a better understanding of the disease mechanisms. The inventors show an abnormal mTOR pathway activation in OS lesional skin. Topical treatment with 1% Sirolimus shows good tolerance and partial but real efficacy on budding, inflammatory and hyperkeratotic lesions of the sole was observed in the treated patient. Accordingly, the present invention relates to a method of treating Olmsted syndrome in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an mTOR inhibitor. | 2020-04-30 |
20200129487 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND - Provided are a novel cancer treatment method and immunostimulant which exhibit a remarkably excellent antitumor effect with little side effects. An antitumor agent and an immunostimulant include an azabicyclo compound and an immune checkpoint molecule regulator which are administered in combination. | 2020-04-30 |
20200129488 | DEMENTIA THERAPEUTIC AGENT COMBINING PYRAZOLOQUINOLINE DERIVATIVE AND MEMANTINE - There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (I): | 2020-04-30 |
20200129489 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHY- RIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA - The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma. | 2020-04-30 |
20200129490 | USE OF AROMATIC RING DRUG IN INHIBITING KEY TRANSCRIPTION FACTOR OF MALIGNANT MELANOMA - Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description. | 2020-04-30 |
20200129491 | METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY - Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents. | 2020-04-30 |
20200129492 | TREATMENT OF CANCER WITH DIHYDROPYRIDINES - Provided are methods and compositions for treating cancer. An embodiment of a method includes administering an effective amount of at least one dihydropyridine, such as lercanidipine, manidipine, nitrendipine, nicardipine, nisoldipine, and any combination thereof. A dihydropyridine may be administered in combination with loperamide. | 2020-04-30 |
20200129493 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF - The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same. | 2020-04-30 |
20200129494 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR - The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material. | 2020-04-30 |
20200129495 | EBASTINE TOPICAL COMPOSITION - Provided herein is a topical composition for treatment of a hair-loss related condition or disease and related methods for making and using the topical composition. The topical composition generally comprises ebastine dissolved in a solvent. In some exemplary embodiments, the solvent comprises a monohydric aliphatic alcohol and an ester. In some exemplary embodiments, the solvent comprises a polyol. | 2020-04-30 |
20200129496 | MUSCARINIC AGONISTS - This invention relates to compounds that are agonists of the muscarinic M | 2020-04-30 |
20200129498 | COMBINATION THERAPY - Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt. | 2020-04-30 |
20200129499 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT - The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor. | 2020-04-30 |
20200129500 | NLRP3 MODULATORS - The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human). | 2020-04-30 |
20200129501 | DEMENTIA THERAPEUTIC AGENT COMBINING PYRAZOLOQUINOLINE DERIVATIVE AND DONEPEZIL - There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): | 2020-04-30 |
20200129502 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2020-04-30 |
20200129503 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE - The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized. | 2020-04-30 |
20200129504 | COMPOSITIONS OF PLINABULIN AND USE THEREOF - Disclosed herein are compositions and methods of preventing and/or treating or reducing immunotherapy mediated adverse events by administering plinabulin. Some embodiments relate to treatment of immunotherapy related inflammation by administering plinabulin. Some embodiments relate to treatment of psoriasis and/or inflammation by administering plinabulin. | 2020-04-30 |
20200129505 | Topical Brimonidine Tartrate Ophthalmic Solution - The present invention provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a non-ionic cellulosic polymer, the solution having a pH less than 6.5. The present invention also provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a benzododecinium halide. Also provided are methods of manufacture, use and method of reducing intraocular pressure in the patient in need thereof. | 2020-04-30 |
20200129506 | PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG - The invention relates to aqueous pharmaceutical compositions comprising the compound 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl) acetamide; glycine; polysorbate 20; and an aqueous phosphate buffer, wherein the relative amounts are as described in the description, wherein the pH of said pharmaceutical composition is between about 7 and 8; to lyophilized pharmaceutical compositions prepared from said aqueous compositions, and to reconstituted aqueous compositions thereof which are suitable for i.v. administration. The invention further relates to processes for the preparation of said compositions, and to their use for the treatment of diseases and disorders which are related to IP receptor. | 2020-04-30 |
20200129507 | TREATMENT OF PROSTATE CANCER - Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. | 2020-04-30 |
20200129508 | PHARMACEUTICAL COMPOSITION COMPRISING SUBSTANCE INHIBITING ENZYMATIC ACTIVITY OF PEROXIREDOXIN 2 AS EFFECTIVE INGREDIENT FOR TREATMENT OF COLORECTAL CANCER - The present invention relates to a pharmaceutical composition for treating colorectal cancer including a material inhibiting the enzyme activity of peroxiredoxin 2 as an active ingredient, and more specifically, to a pharmaceutical composition for treating colorectal cancer, which exhibits the effect of reducing colon polyps via increase of active β-catenin degradation by inhibiting the activity of peroxiredoxin 2, based on the mechanism that promotes colorectal tumor by the interaction between peroxiredoxin 2 (PrxII) and tankyrase (TNKS) in an APC-mutant cell. | 2020-04-30 |
20200129509 | DOSING REGIMEN - The invention relates to a method of treating AML in a subject having a white blood cell (WBC) count of less than about 10,000 cells/microliter, and/or a cytogenetic risk classification according to the US Southwest Oncology Group (SWOG) that is not unfavourable, and/or the subject falls within a classification selected from antecedent myelodysplastic syndrome (MDS), antecedent myeloproliferative neoplasm (MPN), and antecedent myelodysplastic/myeloproliferative neoplasm (MDS/MPN), wherein the method comprises (i) a first treatment cycle comprising administering decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and (ii) a second treatment cycle comprising administering sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer. | 2020-04-30 |
20200129510 | SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST - The present invention relates to a P2Y12 receptor antagonist selected from the group consisting of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4 carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, and (1S,2R,3S,4R)-4-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]cyclopentane-1,2,3-triol, or a pharmaceutically acceptable salt thereof, for use as a medicament by subcutaneous or intradermal administration. | 2020-04-30 |
20200129511 | COMPOUNDS AND METHODS FOR TREATMENT OF NAFLD AND NASH - The present invention relates to 4-[6-(6-Methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester (Compound 1), pharmaceutically acceptable salts, solvates, and hydrates thereof that modulate the activity of the GPR119 receptor. Compound 1 and pharmaceutical compositions thereof are directed to methods useful in the treatment of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and conditions related thereto. | 2020-04-30 |
20200129512 | NOVEL ANTI-INFLAMMATORY AGENTS - Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds. | 2020-04-30 |
20200129513 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES - The invention provides novel methods and pharmaceutical compositions for treating various hematologic malignancies and related diseases and conditions. | 2020-04-30 |
20200129514 | JAK INHIBITION AS A NOVEL THERAPY FOR PREVENTING TUMORS IN PEUTZ-JEGHERS SYNDROME - Treatment with the Jak1/2 inhibitor ruxolitinib results in a dramatic decrease in polyposis for organisms with Peutz-Jeghers Syndrome. | 2020-04-30 |
20200129515 | Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives - The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention al so relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention al so provides a method for manufacture of medicaments useful in the treatment of such disorders. | 2020-04-30 |
20200129516 | NOVEL EGFR MODULATORS AND USES THEREOF - The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways. | 2020-04-30 |
20200129517 | COMBINATION THERAPY FOR TREATMENT OF HEMATOLOGICAL DISEASES - The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid. | 2020-04-30 |
20200129518 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139 - The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: | 2020-04-30 |
20200129519 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER - The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SIV1ARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter). | 2020-04-30 |
20200129520 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE - Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans. | 2020-04-30 |
20200129521 | METHOD AND COMPOSITION FOR TREATING EPILEPSY - A method of treating a subject suffering from epilepsy includes administering an effective amount of a cholecystokinin-2 receptor antagonist or a pharmaceutical acceptable salt thereof to the subject. A pharmaceutical composition includes the cholecystokinin-2 receptor antagonist or a pharmaceutical acceptable salt thereof as active ingredient, one or more antiepileptic compounds, and a pharmaceutically acceptable excipient. | 2020-04-30 |
20200129522 | COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION - The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence. | 2020-04-30 |